TIAA CREF Investment Management LLC cut its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 24.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 309,682 shares of the biopharmaceutical company’s stock after selling 99,270 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.69% of Vanda Pharmaceuticals worth $5,048,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Vanda Pharmaceuticals by 26.4% in the 1st quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock valued at $34,920,000 after acquiring an additional 521,669 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Vanda Pharmaceuticals by 1,544.3% in the 1st quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock valued at $34,783,000 after acquiring an additional 2,333,400 shares during the last quarter. FMR LLC boosted its stake in shares of Vanda Pharmaceuticals by 60.7% during the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after purchasing an additional 604,900 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Vanda Pharmaceuticals by 65.3% during the 1st quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after purchasing an additional 370,900 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Vanda Pharmaceuticals by 13.9% during the 2nd quarter. Teachers Advisors LLC now owns 610,338 shares of the biopharmaceutical company’s stock worth $9,949,000 after purchasing an additional 74,477 shares during the last quarter. 86.45% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “TIAA CREF Investment Management LLC Reduces Position in Vanda Pharmaceuticals Inc. (VNDA)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/27/vanda-pharmaceuticals-inc-vnda-shares-sold-by-tiaa-cref-investment-management-llc.html.
Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Wednesday, October 18th. ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Piper Jaffray Companies set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 19th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Oppenheimer Holdings, Inc. set a $21.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Vanda Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $21.29.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ VNDA) opened at 14.10 on Friday. The firm’s market cap is $632.50 million. The firm has a 50-day moving average of $17.24 and a 200 day moving average of $15.77. Vanda Pharmaceuticals Inc. has a 12 month low of $12.70 and a 12 month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. The business had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. Vanda Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 EPS. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.43) EPS for the current fiscal year.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.